Clinical Studies Sponsored by Amicus Therapeutics

A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)

A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects

Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

Natural History Study of Batten Disease

A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Migalastat Food Effect Study

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Expanded Access for ATB200/AT2221 for the Treatment of IOPD

A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18

Open-Label Phase 3 Long-Term Safety Study of Migalastat

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease